The guideline is published on World AIDS Day, December 1, 2025, to raise awareness of new approaches to prevention.

Pre-exposure prophylaxis involves an HIV-negative person starting antiretroviral medications before potential HIV exposures occur in order to prevent infection. Postexposure prophylaxis involves taking 28 days of antiretrovirals right after a potential exposure to HIV.

“Canada is not at all on track to achieve its goal of eliminating HIV as a public health threat by 2030. Our aim with this guideline is to support front-line health care providers, policy-makers, community members, and others in expanding the use of these safe and effective tools for preventing HIV,” says Dr. Darrell Tan, lead author and infectious disease physician at St. Michael’s Hospital, Toronto, Ontario. “A wide array of PrEP and PEP options now exists in Canada. We need to urgently expand their use until all people have equitable access to prevention strategies that they find suitable.”

HIV infections in Canada are concentrated in specific populations, with 38% of new infections in gay, bisexual, and other men having sex with men (GBM); 25% in people who inject drugs (PWID); and 4% in GBM-PWID. More than one-third of infections occur in females. Some Indigenous communities are particularly heavily affected, with more cases in Saskatchewan and Manitoba than the national average.

The guideline, an update to 2017 guidance, was developed through the Canadian Institutes of Health Research (CIHR) Pan-Canadian Network for HIV and STBBI (sexually transmitted and blood-borne infections) Clinical Trials Research (CTN+). It includes easy reference tables with recommendations on medication regimens, indications, monitoring, and more.

Key differences from the 2017 guideline include the “explicit inclusion of self-identified need as a reason for PrEP initiation” and the expanding range of available PrEP choices, with newer regimens including an injection given every 2 months.

The authors’ aim is to support clinical decision-making in primary care, infectious diseases, emergency medicine, sexual health, nursing, pharmacy, and related disciplines, as well as community workers who promote PrEP and PEP.

“Because lack of PrEP and PEP awareness among key populations and clinicians is a common barrier to implementation, public health officials, professional societies, and other trusted authorities should play leadership roles in promoting these strategies in collaboration with community organizations and tracking uptake in conjunction with HIV surveillance data,” the authors write. “Information should be framed in a positive light to counteract the stigma and apprehension that sometimes surround PrEP and PEP.”

The post New guideline on pre-exposure and postexposure HIV prevention appeared first on Pharmacy Update Online.

But even with this positive news about increasing use of pre-exposure prophylaxis or PrEP, the study also suggests that health care providers and public health agencies could do more to promote consistent use of these medications.

The new study, done by a team at the University of Michigan Medical School, uses national pharmacy data to look at prescriptions for oral PrEP from 2016 to 2023 among people ages 18 to 25. It’s published in the Journal of General Internal Medicine.

At the start of the study period, 26 of every 100,000 U.S. young adults filled a prescription for PrEP, but this rose to more than 208 by the end of 2023. Prescription dispensing was lower for those ages 18 to 21 than for those ages 22 to 25.

However, the length of time that a person kept refilling their prescription dropped by more than two weeks during this time. This may suggest inconsistent use of PrEP, or trouble keeping up with the regular appointments and tests needed to continue the medication.

It’s the first large study to focus just on this age group, which has an especially high risk of HIV transmission. PrEP, when taken consistently and as prescribed, can reduce the chances of acquiring HIV through sex by 99%.

It’s also an age group that doesn’t see the doctor often, notes Nina Hill, M.D., the lead author of the study.

Hill is a general internist and pediatrician at U-M, a National Clinician Scholar at the U-M Institute for Healthcare Policy and Innovation, and a postdoctoral fellow in the Susan B. Meister Child Health Evaluation and Research Center.

“This is a patient population we often neglect in health care, because we we don’t think about them belonging to pediatric care or adult care, and their stage of cognitive development means they underestimate their STI risk in general — yet they’re one of the highest risk groups for a new diagnosis of HIV,” she said. “We’re encouraged to see more prescribing over time, but the question remains: are we getting it to the highest-risk patients?”

She notes the number of steps needed to get to consistent PrEP use: getting screened by a provider or online screening tool to determine if PrEP is appropriate, seeing a provider for the initial exam and tests for HIV and other sexually transmitted infections (STIs), receiving and filling a prescription, and keeping up with regular tests of kidney function, HIV and other STIs every three to six months.

Even patients who decide to take their PrEP pills on an episodic rather than daily basis – before time periods when they will be sexually active with new partners, for instance – need to have consistent access.

Either way, she says, it’s important for young adults, their health care providers, and the adults they trust most to discuss their sexual health, and to be aware of the availability of PrEP and its power to prevent HIV.

More about the findings

In all, Hill and her colleagues looked at 1.45 million prescriptions dispensed to nearly 240,000 young adults with an average age of 22. Most (87%) were male, but Hill notes that certain women are also at risk for HIV and might be eligible for PrEP.

Just over a third of the young adults taking PrEP lived in the southern U.S., an area where HIV transmission is especially high. And the rate of PrEP dispensing started lowest but rose fastest in this region during the study period.

The study covers a period when the first PrEP medication, introduced in 2012 under the brand name Truvada, also became available as a generic drug in 2020, and a second oral PrEP option called Descovy went on the market in 2019. Though an injectable form of PrEP received approval in 2021, few young adults received this treatment so they were excluded from the study.

More than 70% of the prescriptions during the study period were for Truvada or its generic equivalent.

Hill and her colleagues also looked at what kind of health care provider prescribed PrEP to each person who filled a prescription.

Nurse practitioners accounted for 39% of prescriptions, with family medicine or general practitioners accounting for 22%, and internal medicine physicians and physician assistants accounting for 14% and 11%, respectively.

Although emergency medicine physicians accounted for a very small percentage overall, the number of prescriptions written by them increased tenfold during the study period.

PrEP has been recommended since 2019 by the U.S. Preventive Services Task Force for adolescents and adults who have an increased risk of acquiring HIV.  All individuals should be screened for HIV at least once in their lifetime between ages 15 and 65 years. Under the Affordable Care Act, most insurance programs must make PrEP and HIV screening available to patients at no cost if they meet USPSTF criteria.

However, the status of that coverage is the subject of a case called Braidwood v. Kennedy that was recently heard before the U.S. Supreme Court; a ruling is expected soon.

More information about PrEP is available via the HIV.gov site: https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis .

Hill and senior author Kao-Ping Chua, M.D., Ph.D., and their co-author Sijia He, M.S., are part of the Susan B. Meister Child Health Evaluation and Research Center, which Chua directs. Hill is supported by the National Clinician Scholars Program, the Susan B. Meister Child Health Evaluation and Research Center, and a training grant (T32HS000053) from the Agency for Healthcare Research and Quality.

National Trends in HIV Pre-Exposure Prophylaxis Dispensing to Young Adults, 2016–2023, Journal of General Internal Medicine, DOI:10.1007/s11606-025-09574-8

The post More young adults than ever take HIV-prevention medication, but gaps remain appeared first on Pharmacy Update Online.

Today, thanks to that sequence of contributions, the first HIV drug to offer long-lasting protection from infection — eliminating the need for people to take a daily pill — exists. For their role in ensuring that drug, lenacapavir, came to life and to market, the AAAS Mani L. Bhaumik Breakthrough of the Year Award is being awarded to Wesley Sundquist, chair of the University of Utah Department of Biochemistry; Moupali Das, vice president, Clinical Development, HIV Prevention & Pediatrics at Gilead Sciences; and Yvette Raphael, co-founder and executive director of Advocacy for Prevention of HIV in Africa .

“These individuals represent the three arms of what is necessary to create new science and then translate it for the world in a way that is really able to make a difference,” said Megan Ranney, dean of the Yale School of Public Health and part of the committee — convened by Science journals’ Editor-in-Chief Holden Thorp — that selected the winners.

“I was excited about how these three tell the story of the journey required to bring a drug into existence,” said committee member William Powderly, co-director of the Division of Infectious Diseases at Washington University School of Medicine. “It takes multiple people, skillsets and partners.”

As of 2023, 39.9 million people globally were living with HIV, newly infecting more than 1 million people a year.

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on HIV’s cone-shaped capsid protein, gets close, almost completely preventing new HIV infections from occurring. The drug protects people for six months with each shot.

“This drug is extraordinary — the closest thing to a vaccine that we have,” said Ranney. She explained that she and many of her peers in the public health community entered the field at the height of the AIDS pandemic, in the 1980s and 1990s. “This medication is beyond the wildest dreams of what many of us could have imagined.”

Recognizing the people behind such significant scientific developments is a central philosophy for donor Mani L. Bhaumik, Ph.D. — a physicist with myriad contributions to the development of high-powered lasers — as well as for AAAS and the Science family of journals.

“Studying intractable parts of the physical world, like a virus capsid, is critical to scientific innovation,” said Bhaumik. “And persisting to ensure that insights from basic research insight can be applied and that they are trusted by those who they will serve is critical — now more than ever. I’m delighted to see this year’s recognition go to people across sectors whose thorough approach made such a valuable contribution.”

The Mani L. Bhaumik Breakthrough of the Year Award was established in 2022 with a $11.4 million pledge from Bhaumik: the largest in the organization’s history. The award supports a $250,000 cash prize annually for up to three scientists or researchers whose work best underpins the Science Breakthrough of the Year, the journal’s choice of the top research advance of the year. In 2024, Science named lenacapavir the latest Breakthrough. 

Mapping HIV’s capsid

Sundquist, who moved to the University of Utah as an assistant professor in 1992, played a key role in the development of the drug, though his work was not immediately recognized. “Sundquist spent countless hours in the lab, made a critical discovery, and then watched it sit on the shelf for a while, which can happen in basic science,” said Ranney.

His contribution — which he embarked upon as he started his Utah-based lab — was elucidating the structure and functions of the HIV virus’s capsid protein. Sundquist focused on the capsid because he was aware that HIV deaths were increasing globally and that most scientists studying HIV treatments were looking at the virus’s enzymes. “We wanted to work on an aspect of the problem that was unique,” he said, “and we were drawn to the unusual cone-shape of the capsid.”

Until Sundquist’s work, scientists thought the capsid, which encloses the virus’s genetic material, was largely a structural element. They did not see it as a particularly “druggable” target, especially compared to enzymes, in part because it was thought to be highly stable.

In 1996, working with a team, Sundquist published a paper in Science that defined the capsid’s architecture. That laid the groundwork for a study in 2003 in the Journal of Virology, in which he and colleagues showed that if the HIV capsid was disrupted, even in minor ways, viral replication was disrupted too.

“That was unexpected,” said Sundquist.

Clinical trials purposefully designed

Even as these critical discoveries were made, however, it wasn’t obvious that the capsid would be easily turned into a drug target. For his part, though, Sundquist didn’t feel it was very long after he and his colleagues published their 2003 results that Gilead Sciences contacted them.

Tomas Cihlář, a virologist at the company, visited Sundquist’s labs. Impressed with his discoveries, Cihlář took them back to his colleagues. The Gilead team wanted to see if they could use Sundquist’s insights about how to hinder viral replication to design HIV drugs with longer acting power for people living with HIV; while the standard of care treatment — combination antiretroviral therapy — worked well, it required daily medication.

A dedicated group of scientists at Gilead Sciences showed perseverance as it took more than a decade (beginning around 2006) to develop a drug based on Sundquist’s findings. To do so, John Link, then-vice president of Medicinal Chemistry at Gilead, and his colleagues screened thousands of molecules to identify an effective capsid inhibitor.
“We sometimes think about industry as not having staying power,” said Ranney. “But it was something like 15 years here — fits and starts — and Gilead as an institution kept supporting capsid inhibitors.”

The molecule’s properties meant its effects could be extended over six months, a promising option for patients who struggled with daily medications.

Gilead ran the first trial for people with HIV involving an injectable version of lenacapavir in 2018. “I was a medical monitor for the first Phase 1 trial,” said Das, a winner of this year’s Bhaumik Breakthrough of the Year Prize on behalf of the many Gilead Sciences team members working on lenacapavir. This meant Das, a trained physician, provided expert guidance to confirm the safety of trial participants.

At that time, Gilead was focused on evaluating lenacapavir for treatment of HIV. But the reality was there were already effective treatments, like antiretrovirals. Meanwhile, there were still many people in the world at high risk of acquiring HIV.

“I remember seeing results from the first lenacapavir treatment study and thinking this drug — because of its molecular properties — might be very good for prevention, too.” Das said, “I was immediately thinking: how could we use this for prevention?”

The next step forward was figuring out the best way to evaluate this drug for preventing HIV.

“Gilead had already established the company as leaders in the use of oral antiretroviral agents as pre-exposure prophylaxis” said Myron Cohen, director of the Institute of Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, and who also sat on the committee who selected the winners. “But many people found it difficult to maintain usage of daily oral pills. Development of long-acting agents, especially injectable agents, became an important goal.”

When Gilead Sciences made this decision, Das played a crucial role. “She was the pivotal person who created studies to garner proof that it worked for prevention, too,” said Powderly.

Her leadership was essential in designing the clinical trials, known as PURPOSE 1 and PURPOSE 2, which began in 2021 and are among the most comprehensive HIV prevention trial programs ever conducted. The trials were carefully shaped to include people most in need of preventative care — and people most underserved by past trials. This involved establishing trial sites in locations where infections were happening most.

“There were lots of times where we had to change hearts and minds in designing this trial program because we did a lot differently,” she said. Much of this related to the novel design and lenacapavir itself, but also to who was included. Das recalled a story of a young African adolescent woman who was pregnant and who came to a stakeholder meeting in Kigali, Rwanda. That meeting, organized by Gilead, included community advocates, government officials, regulators, ethicists, site staff and Pre-Exposure Prophylaxis clinical trial investigators whom Gilead had convened to discuss how best to design and implement PrEP trials in cisgender women. “’Make sure people like me have a chance in the trials,’ this woman had said to us. I’ll never forget her.”

Das firmly believes better science happens when everyone is included. “It’s not charity,” she said. “It’s good science.”

The PURPOSE 1 trial evaluated lenacapavir in cisgender women and in adolescent girls in sub-Saharan Africa and Uganda, where stigma means some women have challenges using daily oral PrEP products. Some of the women in the trial became pregnant. Results from PURPOSE 1, published in July 2024, showed that twice-yearly lenacapavir led to 100% efficacy in preventing infections, a tremendous result. “It was so exciting to have the first results for lenacapavir for HIV prevention be in women,” said Das.

For PURPOSE 2, Das and her team recruited participants from places disproportionately affected by HIV and underrepresented in past HIV clinical trials, including parts of the United States, Brazil, Thailand, South Africa, Peru, Argentina, and Mexico. The trial evaluated lenacapavir for prevention of HIV in a diverse range of cisgender men and gender-diverse people. Results, published in November 2024, showed the drug reduced new infections by 96%.

Powderly said years-long work from researchers at Gilead Sciences leading up to Das’s efforts was critical, “and without her enthusiasm and drive, that final hurdle — the studies and trials for prevention — would have been much harder.”

‘The human voice matters’

Keeping the people most in need of HIV drugs at the center of the PURPOSE trials, as Das did, was possible because of a key partner — another winner of this year’s Bhaumik Breakthrough of the Year Award: Yvette Raphael.

Das and Raphael met in Kigali, Rwanda in 2019, two years before the PURPOSE trials started, at the same stakeholder meeting where Das and the group convened by Gilead heard from the young pregnant African woman about including people like her in the trials. “Yvette really wanted to know what we were going to do differently,” said Das.

Raphael, an HIV prevention advocate and community leader living with HIV, had previously engaged in trials of HIV drugs. “We knew past trials had made mistakes,” she said.

“Raphael was well-recognized as a tireless and thoughtful advocate for the development of HIV prevention strategies for women,” said Cohen.  “Her involvement in the development of lenacapavir – in trusted communication with Gilead and trial participants and their communities – was a critical requirement for the success of these studies.”

Raphael fought to make sure people affected by HIV had access to information about new treatment options, including long-acting treatments that could improve quality of life. In Africa, especially among African women, problems with HIV preventative strategies — largely in the form of daily pills — were ongoing. Drugs that worked in men were not working in women in part because it was harder, for social reasons, for women to take a pill every day.

“An injection would have been better for women,” said Powderly. “But community trust and involvement were critical.”

Raphael, who served as Chair of the PURPOSE 1 Advisory Board from 2019 to 2024, told Gilead about the major challenges in the African community.

“For lenacapavir trials, we wanted young people to be part so that the drug could be approved for them from the start,” said Raphael. Since young people need parental consent, she helped advise parents considering whether their adolescent children could participate.

“It was also very important for pregnant women to be included,” said Raphael. “We wanted to be sure that once this drug was approved, pregnant women could get it, too.”

Their efforts paid off, and the PURPOSE 1 trial came together, including women, pregnant women and adolescents.

“The clinical trials would never have been as successful as they were had it not been for Raphael,” said Thorp.

“The human voice matters as much as the science to get to translation in the real world,” said Ranney. “Yvette’s leadership is a gorgeous exemplar of how great science is done.”

For her part, Raphael said her collaboration with Das, where they both learned from and pushed each other, was critical.

“I’d like to recognize Moupali’s fearlessness for creating greater participation from the community,” said Raphael. “We called her the ‘Das-rupter’ … I’ve been participating in HIV prevention trials for 25 years, and every time, we said we’d do better. I think with Moupali, this is the best we have done.”

Ensuring that the people most impacted by a drug are part of trials provides another benefit that comes later. “We can discover drugs and see they are successful in trials,” said Raphael, “but the next outcomes won’t be as good if there’s nobody to ‘own’ these innovations, and to advocate for them to be affordable and accessible. We did not want this drug to sit on a shelf.”

For Raphael, the outcome of the trials has been nothing short of a miracle. “It’s amazing that you need injections just twice a year.” She said the biggest surprise to her was the 100% efficacy in PURPOSE 1. “It was also surprising that it was such a short trial.” In 2024, the trial was stopped early because of success it had already shown, which meant the drug could become available sooner. “When that news broke,” she said, “Africa stood still.”

“The PURPOSE 1 and 2 trials are exemplars for how to do a better job making sure people who will one day want to use the medication have a voice,” said Ranney. “This will speed the implementation of the drug on the other side.”

Raphael knows the research that made this life-changing drug a reality started decades ago, in Sundquist’s lab, with studies of a viral capsid.

“This work changed how people think about viral capsids,” said Sundquist. “It meant that other people could think about capsids as drug targets.”

The future of life-changing basic research

Today, however, as funding cuts to basic research are happening across the U.S., there is growing concern. “If there’s a weakness in the pipeline and people don’t know what to target,” said Sundquist, “then drugs don’t get developed.”

“My worry as we watch funding to science get cut,” said Ranney, “is we won’t fully feel the ripple effects for 10 or 20 years because it can take that long for discoveries to make their way into lives of families and individuals.”

Raphael is concerned that cuts mean “life-saving drugs will fall out the window.” While lenacapavir is likened to a vaccine for HIV, it is not one. “This is not the last breakthrough for HIV prevention. Without continuous funding for prevention and advocacy, we won’t have tomorrow’s breakthroughs,” she said.

Programs like the President’s Emergency Plan for AIDS Relief, or PEPFAR — which has been a key component of global health since it was founded by President George W. Bush in 2003 — are critical to supporting HIV prevention. A study published in Annals of Internal Medicine in February of this year reported that eliminating PEPFAR would lead to 601,000 HIV-related deaths and 565,000 new HIV infections in South Africa alone over 10 years.

As of April 30, 2025, PEPFAR’s current short-term authorization has expired. “The logical funding for distributing lenacapavir in the developing world would come from PEPFAR, a program that has been very successful, saving so many lives, but is now basically on life support,” said Sundquist. “This means lenacapavir is really at risk of not being broadly distributed in the places that need it the most.”

Ranney said her hope is that the selection of winners for this year’s prize serves to remind science funders of the importance of all stages of scientific innovation and of giving freedom to science to pursue great ideas. “It’s important to fund basic research as we never know what is going to be the next world-changing discovery.”

The post The road to lenacapavir, a breakthrough HIV treatment appeared first on Pharmacy Update Online.

The center, made up of leading scientists from UCLA, Charles R. Drew University of Medicine and Science, the Friends Research Institute and the RAND Corp., has worked for 25 years to combat the HIV/AIDS epidemic both locally and globally through scientific research and treatments, network building and collaborations with community and agency partners.

The new federal funding will support a research agenda aimed at reducing HIV transmission across Southern California, the nation and the world — in line with the U.S. Department of Health and Human Service’s initiative to end the epidemic in the United States by 2030.

The grant program will be directed by Steven Shoptaw, a professor of family medicine and of psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA, where he is also vice chair of research in family medicine.

“This award is a testament to the unwavering commitment of our scientists and community partners,” Shoptaw said. “With this funding, we look forward to pursuing innovative, high-impact approaches to address the HIV epidemic and the conditions that drive it.”

Currently, approximately 38 million people globally and 1.2 million nationally are living with HIV, with about 35,000 new cases diagnosed each year in the U.S., according to the Centers for Disease Control and Prevention.

Under the new grant, CHIPTS will guide a regional strategy for Southern California that aligns with the HHS national Ending the HIV Epidemic plan. The center will support research aimed at developing and improving multifaceted approaches to suppressing the virus in people already infected with HIV and preventing infections among at-risk populations, with a particular focus on those with mental health and substance use disorders and those who face social and structural barriers in accessing health care.

In these efforts, CHIPTS will work closely with scientific, community and public health partners while promoting efforts to improve diversity, equity and inclusion among the next generation of HIV investigators.

“The center plays a critical role in advancing HIV prevention science that innovates in combination prevention strategies and shifts policy to influence health outcomes,” said CHIPTS co-director Dr. Raphael Landovitz, a professor of medicine at the Geffen School. “We are extremely grateful for the opportunity to continue and expand our work in this next cycle.”

The National Institute of Mental Health is part of the National Institutes of Health.

The post UCLA’s HIV prevention and treatment center receives $7.5 million grant from NIH appeared first on Pharmacy Update Online.